157 related articles for article (PubMed ID: 11197865)
21. Gene therapy for primary adaptive immune deficiencies.
Fischer A; Hacein-Bey-Abina S; Cavazzana-Calvo M
J Allergy Clin Immunol; 2011 Jun; 127(6):1356-9. PubMed ID: 21624615
[TBL] [Abstract][Full Text] [Related]
22. Gene therapy of primary T cell immunodeficiencies.
Fischer A; Hacein-Bey-Abina S; Cavazzana-Calvo M
Gene; 2013 Aug; 525(2):170-3. PubMed ID: 23583799
[TBL] [Abstract][Full Text] [Related]
23. Progress towards hematopoietic stem cell gene therapy.
Kurre P; Kiem HP
Curr Opin Mol Ther; 2000 Aug; 2(4):400-11. PubMed ID: 11249770
[TBL] [Abstract][Full Text] [Related]
24. [Gene therapy for adenosine deaminase deficiency].
Sakiyama Y; Ariga T; Ohtsu M
Nihon Rinsho; 2005 Mar; 63(3):448-52. PubMed ID: 15773344
[TBL] [Abstract][Full Text] [Related]
25. In vivo kinetics of transduced cells in peripheral T cell-directed gene therapy: role of CD8+ cells in improved immunological function in an adenosine deaminase (ADA)-SCID patient.
Kawamura N; Ariga T; Ohtsu M; Kobayashi I; Yamada M; Tame A; Furuta H; Okano M; Egashira M; Niikawa N; Kobayashi K; Sakiyama Y
J Immunol; 1999 Aug; 163(4):2256-61. PubMed ID: 10438969
[TBL] [Abstract][Full Text] [Related]
26. Serial transplantations in nonobese diabetic/severe combined immunodeficiency mice of transduced human CD34+ cord blood cells: efficient oncoretroviral gene transfer and ex vivo expansion under serum-free conditions.
Gammaitoni L; Lucchi S; Bruno S; Tesio M; Gunetti M; Pignochino Y; Migliardi G; Lazzari L; Aglietta M; Rebulla P; Piacibello W
Stem Cells; 2006 May; 24(5):1201-12. PubMed ID: 16410386
[TBL] [Abstract][Full Text] [Related]
27. In vivo transduction by intravenous injection of a lentiviral vector expressing human ADA into neonatal ADA gene knockout mice: a novel form of enzyme replacement therapy for ADA deficiency.
Carbonaro DA; Jin X; Petersen D; Wang X; Dorey F; Kil KS; Aldrich M; Blackburn MR; Kellems RE; Kohn DB
Mol Ther; 2006 Jun; 13(6):1110-20. PubMed ID: 16651028
[TBL] [Abstract][Full Text] [Related]
28. Amendment to Clinical Research Project. Project 90-C-195. April 1, 1993. Treatment of severe combined immunodeficiency disease (SCID) due to adenosine deaminase deficiency with autologous lymphocytes transduced with a human ADA gene.
Dunbar C; Chang L; Mullen C; Ramsey WJ; Carter C; Kohn D; Parkman R; Lenarsky C; Weinberg K; Wara D; Culver KW; Anderson WF; Leitman S; Fleisher T; Klein H; Shearer G; Clerici M; McGarrity G; Bastian J; Hershfield MS
Hum Gene Ther; 1999 Feb; 10(3):477-88. PubMed ID: 10048399
[No Abstract] [Full Text] [Related]
29. Update on gene therapy for hereditary hematological disorders.
Herzog RW; Arruda VR
Expert Rev Cardiovasc Ther; 2003 Jul; 1(2):215-32. PubMed ID: 15030282
[TBL] [Abstract][Full Text] [Related]
30. Gene therapy for severe combined immune deficiency.
Qasim W; Gaspar HB; Thrasher AJ
Expert Rev Mol Med; 2004 Jul; 6(13):1-15. PubMed ID: 15236670
[TBL] [Abstract][Full Text] [Related]
31. Comparison of five retrovirus vectors containing the human IL-2 receptor gamma chain gene for their ability to restore T and B lymphocytes in the X-linked severe combined immunodeficiency mouse model.
Avilés Mendoza GJ; Seidel NE; Otsu M; Anderson SM; Simon-Stoos K; Herrera A; Hoogstraten-Miller S; Malech HL; Candotti F; Puck JM; Bodine DM
Mol Ther; 2001 Apr; 3(4):565-73. PubMed ID: 11319919
[TBL] [Abstract][Full Text] [Related]
32. The leukemogenic risk of integrating retroviral vectors in hematopoietic stem cell gene therapy applications.
Kang EM; Tisdale JF
Curr Hematol Rep; 2004 Jul; 3(4):274-81. PubMed ID: 15217557
[TBL] [Abstract][Full Text] [Related]
33. Gene therapy for inherited immunodeficiencies.
Howe S; Thrasher AJ
Curr Hematol Rep; 2003 Jul; 2(4):328-34. PubMed ID: 12901330
[TBL] [Abstract][Full Text] [Related]
34. Management options: SCIDS with adenosine deaminase deficiency.
Hilman BC; Sorensen RU
Ann Allergy; 1994 May; 72(5):395-403; quiz 403-4, 407. PubMed ID: 8179225
[TBL] [Abstract][Full Text] [Related]
35. Gene therapy for primary immunodeficiency diseases: recent progress and misgivings.
Ariga T
Curr Pharm Des; 2006; 12(5):549-56. PubMed ID: 16472146
[TBL] [Abstract][Full Text] [Related]
36. Strategies for retrovirus-based correction of severe, combined immunodeficiency (SCID).
Fischer A; Hacein-Bey-Abina S; Cavazzana-Calvo M
Methods Enzymol; 2012; 507():15-27. PubMed ID: 22365767
[TBL] [Abstract][Full Text] [Related]
37. Investor Outlook: Rising from the Ashes; GSK's European Approval of Strimvelis for ADA-SCID.
Schimmer J; Breazzano S
Hum Gene Ther Clin Dev; 2016 Jun; 27(2):57-61. PubMed ID: 27267267
[TBL] [Abstract][Full Text] [Related]
38. Integration of retroviral vectors induces minor changes in the transcriptional activity of T cells from ADA-SCID patients treated with gene therapy.
Cassani B; Montini E; Maruggi G; Ambrosi A; Mirolo M; Selleri S; Biral E; Frugnoli I; Hernandez-Trujillo V; Di Serio C; Roncarolo MG; Naldini L; Mavilio F; Aiuti A
Blood; 2009 Oct; 114(17):3546-56. PubMed ID: 19652199
[TBL] [Abstract][Full Text] [Related]
39. Gene therapy for adenosine deaminase deficiency.
Aiuti A; Ficara F; Cattaneo F; Bordignon C; Roncarolo MG
Curr Opin Allergy Clin Immunol; 2003 Dec; 3(6):461-6. PubMed ID: 14612670
[TBL] [Abstract][Full Text] [Related]
40. Adenosine deaminase deficiency as the first target disorder in gene therapy.
Onodera M; Sakiyama Y
Expert Opin Investig Drugs; 2000 Mar; 9(3):543-9. PubMed ID: 11060694
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
